Document Classification

Section Type: METHODS

Text: Eligible patients were randomized 1:1 to treatment with olmesartan medoxomil (20 mg/day for 2 weeks ; then 40 mg/day for 2 weeks ; then olmesartan medoxomil/HCTZ 40/12. 5 mg/day for 4 weeks ; then olmesartan medoxomil/HCTZ 40/25 mg/day for 4 weeks) or benazepril (10 mg/day for 2 weeks ; then 20 mg/day for 2 weeks ; then benazepril 20 mg/day plus amlodipine besylate 5 mg/day for 4 weeks ; then benazepril 20 mg/day plus amlodipine besylate 10 mg/day for 4 weeks).